New research targets cartilage regeneration for osteoarthritis

Researchers are developing new methods to combat knee osteoarthritis by targeting the biological processes that cause cartilage deterioration.

Scientists at Stanford Medicine have identified that inhibiting an enzyme called 15-hydroxyprostaglandin dehydrogenase (15-PGDH) can stimulate cartilage regeneration. In studies involving ageing mice, this intervention produced substantial cartilage regrowth and protected against osteoarthritis following knee injuries. The research also showed that the approach could stimulate human cartilage taken during knee replacement surgeries to produce new articular cartilage.

In a separate clinical development, Keck Medicine of USC has launched a clinical trial for an investigational treatment called CX-011. This therapy, administered via a single injection into the knee joint, aims to test safety and tolerability while potentially preventing cartilage loss. The treatment works by interrupting inflammation-related signaling involving the GP130 immune system receptor, which can contribute to a cycle of cartilage damage in osteoarthritic patients.